https://news.bloomberglaw.com/banking-law/ftx-com-assets-frozen-by-bahamas-securities-regulator
Junshi Biosciences And Coherus Biosciences Announced Results Of A Final Analysis Of Overall Survival From Jupiter-02 Phase 3 Trial Of Toripalimab Plus Gemcitabine Plus Cisplatin As The First-line Treatment Recurrent Or Metastatic Nasopharyngeal Carcino…
This final analysis demonstrated a statistically significant and clinically meaningful improvement in overall survival in nasopharyngeal carcinoma patients treated with toripalimab plus chemotherapy compared to